Zacks.com We note that edaravone injection (Bicun and Yidasheng) generated sales of RMB 702.7 million of sales in 2012, down 8.9% due to the loss of tenders. Earlier in the month, Simcere entered into a strategic agreement with Bristol-Myers Squibb Company (BMY ...
Seeking Alpha Both Boda and Simcere produce injectible edaravone drugs that act as neuroprotectives following a stroke. The Boda sale has taken place after Simcere's Chairman offered $503 million to take Simcere private, and the $65 million in sale proceeds will ...
The Pharma Letter Boda is the manufacturer of the stroke management drug, Yidashen, the other injectable edaravone agent on the market, and is the firm's leading product. Simcere accumulated this stake in Boda through equity acquisitions made since 2007. On completion ... and more »
